| A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study R Sun, EJ Limkin, M Vakalopoulou, L Dercle, S Champiat, SR Han, ... The Lancet Oncology 19 (9), 1180-1191, 2018 | 937 | 2018 |
| High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial C Massard, S Michiels, C Ferté, MC Le Deley, L Lacroix, A Hollebecque, ... Cancer discovery 7 (6), 586-595, 2017 | 670 | 2017 |
| Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade N Jacquelot, T Yamazaki, MP Roberti, CPM Duong, MC Andrews, ... Cell research 29 (10), 846-861, 2019 | 199 | 2019 |
| Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial L Verlingue, D Malka, A Allorant, C Massard, C Ferté, L Lacroix, ... European Journal of Cancer 87, 122-130, 2017 | 162 | 2017 |
| Hypermutated tumours in the era of immunotherapy: the paradigm of personalised medicine L Nebot-Bral, D Brandao, L Verlingue, E Rouleau, O Caron, E Despras, ... European journal of cancer 84, 290-303, 2017 | 141 | 2017 |
| Applications of single-cell and bulk RNA sequencing in onco-immunology M Kuksin, D Morel, M Aglave, FX Danlos, A Marabelle, A Zinovyev, ... European Journal of Cancer 149, 193-210, 2021 | 92 | 2021 |
| Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase–mutated intrahepatic cholangiocarcinomas J Delahousse, L Verlingue, S Broutin, C Legoupil, M Touat, L Doucet, ... European Journal of Cancer 90, 83-91, 2018 | 38 | 2018 |
| Matching genomic molecular aberrations with molecular targeted agents: are biliary tract cancers an ideal playground? L Verlingue, A Hollebecque, V Boige, M Ducreux, D Malka, C Ferté European journal of cancer 81, 161-173, 2017 | 30 | 2017 |
| BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 … P Schoffski, BC Cho, A Italiano, HHF Loong, C Massard, ... Journal of Clinical Oncology 39 (15_suppl), 3008-3008, 2021 | 29 | 2021 |
| The spectrum of clinical trials aiming at personalizing medicine C Le Tourneau, M Kamal, M Alt, L Verlingue, V Servois, MP Sablin, ... Chinese clinical oncology 3 (2), 13-13, 2014 | 27 | 2014 |
| High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017; 7 (6): 586–595. doi: 10.1158/2159-8290 C Massard, S Michiels, C Ferté, MC Le Deley, L Lacroix, A Hollebecque, ... doi 10, 2159-8290, 0 | 27 | |
| Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with … A Italiano, L Verlingue, H Prenen, EM Guerra, D Tosi, R Perets, ... Journal of Clinical Oncology 39 (15_suppl), 5510-5510, 2021 | 20 | 2021 |
| A comprehensive approach to the molecular determinants of lifespan using a Boolean model of geroconversion L Verlingue, A Dugourd, G Stoll, E Barillot, L Calzone, A Londoño‐Vallejo Aging Cell 15 (6), 1018-1026, 2016 | 20 | 2016 |
| Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer Y Pradat, J Viot, AA Yurchenko, K Gunbin, L Cerbone, M Deloger, ... Cancer discovery 13 (5), 1116-1143, 2023 | 18 | 2023 |
| Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis R Chebib, L Verlingue, N Cozic, M Faron, P Burtin, V Boige, ... Seminars in oncology 44 (2), 114-128, 2017 | 18 | 2017 |
| Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: entering the back door L Verlingue, A Hollebecque, L Lacroix, S Postel-Vinay, A Varga, ... European Journal of Cancer 92, 1-10, 2018 | 17 | 2018 |
| Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers L Cabel, A Fuerea, L Lacroix, C Baldini, P Martin, A Hollebecque, ... Oncotarget 9 (11), 9741, 2018 | 14 | 2018 |
| Implementing the European society for medical oncology scale for clinical actionability of molecular targets in a comprehensive profiling program: impact on precision medicine … P Martin-Romano, L Mezquita, A Hollebecque, L Lacroix, E Rouleau, ... JCO Precision Oncology 6, e2100484, 2022 | 12 | 2022 |
| Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers A Boilève, L Verlingue, A Hollebecque, V Boige, M Ducreux, D Malka Expert Opinion on Investigational Drugs 30 (4), 401-409, 2021 | 12 | 2021 |
| Prediction of drug approval after phase I clinical trials in oncology: RESOLVED2 G Beinse, V Tellier, V Charvet, E Deutsch, I Borget, C Massard, ... JCO Clinical Cancer Informatics 1, 1-10, 2019 | 12 | 2019 |
